Literature DB >> 11849864

Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption.

Stephan B Felix1, Alexander Staudt, Martin Landsberger, Yvonne Grosse, Verena Stangl, Thomas Spielhagen, Gerd Wallukat, Klaus D Wernecke, Gert Baumann, Karl Stangl.   

Abstract

OBJECTIVES: The objective of this study was to investigate whether immunoadsorption (IA) removes cardiodepressant antibodies from the plasma of patients with dilated cardiomyopathy (DCM), as well as to describe their effects on isolated rat cardiomyocytes.
BACKGROUND: Immunoadsorption induces early hemodynamic improvement in patients with DCM. The mechanisms for this improvement remain to be elucidated.
METHODS: Patients with DCM (n = 11; left ventricular ejection fraction < 30%, cardiac index [CI] < 2.5 l/min per m(2)) were treated with IA on three consecutive days, with one IA session daily, by application of specific antibody columns directed against human immunoglobulin (Ig). Immunoadsorption was also conducted on 500 ml of blood taken from nine healthy donors (control subjects). After passage of plasma, the IA columns were regenerated. Column eluent (CE) was collected and dialyzed (100 kD). Confocal laser scanning microscopy was used to analyze the effects of CE on cell contraction and on Ca(2+)-dependent fluorescence in isolated, field-stimulated adult rat cardiomyocytes loaded with cell-permeable Fluo-3. Immunoprecipitation with different preparations of myocardial protein fractions was used for characterization of cardiotropic antibodies.
RESULTS: During IA, the IgG plasma level decreased from 10.7 +/- 0.6 to 2.4 +/- 0.1 g/l (mean +/- SEM), and the CI increased from 2.2 +/- 0.1 to 2.7 +/- 0.2 l/min per m(2) (p < 0.01). The CE obtained from control subjects did not influence Ca(2+) transients or cell shortening of cardiomyocytes. In contrast, in patients with DCM, the CE collected during the first regeneration cycle of the first IA session caused an immediate and dose-related decrease of Ca(2+) transients (dilution 1:5; -22.7 +/- 5.5%; p < 0.01) and cell shortening (dilution 1:5; -29.9 +/- 6.0%, p < 0.01). Early hemodynamic improvement among the patients correlated with the cardiodepressant effect of CE on the isolated cardiomyocytes. Purification of CE by protein A adsorption indicated that the cardiodepressant substances are antibodies. Immunoprecipitation revealed that the eliminated antibodies are capable of binding to various myocardial proteins.
CONCLUSIONS: Cardiac autoantibodies play a functional role in DCM, and their removal may induce early hemodynamic improvement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11849864     DOI: 10.1016/s0735-1097(01)01794-6

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  29 in total

1.  Effects of immunoadsorption on endothelial function, circulating endothelial progenitor cells and circulating microparticles in patients with inflammatory dilated cardiomyopathy.

Authors:  Daniel Bulut; Michael Scheeler; Lisa Marie Niedballa; Thomas Miebach; Andreas Mügge
Journal:  Clin Res Cardiol       Date:  2011-02-06       Impact factor: 5.460

Review 2.  Autoantibodies and cardiovascular dysfunction: cause or consequence?

Authors:  Yuji Nagatomo; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 3.  Immune cell diversity contributes to the pathogenesis of myocarditis.

Authors:  Xiumeng Hua; Jiangping Song
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

Review 4.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

Review 5.  Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure.

Authors:  Ziya Kaya; Hugo A Katus; Noel R Rose
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

Review 6.  Recent insights into the role of autoimmunity in idiopathic dilated cardiomyopathy.

Authors:  Jason M Lappé; Clara M Pelfrey; W H Wilson Tang
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

Review 7.  [Immunoadsorption for treatment of dilated cardiomyopathy].

Authors:  S B Felix; M Dörr; L R Herda; D Beug; A Staudt
Journal:  Internist (Berl)       Date:  2008-01       Impact factor: 0.743

8.  Immunoadsorption and subsequent immunoglobulin substitution decreases myocardial gene expression of desmin in dilated cardiomyopathy.

Authors:  Angela Kallwellis-Opara; Alexander Staudt; Christiane Trimpert; Michel Noutsias; Uwe Kühl; Matthias Pauschinger; Heinz-Peter Schultheiss; Markus Grube; Michael Böhm; Gert Baumann; Uwe Völker; Heyo K Kroemer; Stephan B Felix
Journal:  J Mol Med (Berl)       Date:  2007-10-09       Impact factor: 4.599

9.  Outcomes of plasma exchange for severe dilated cardiomyopathy in children.

Authors:  Keiichi Koizumi; Minako Hoshiai; Takako Toda; Nobuyuki Katsumata; Hiroaki Kise; Yohei Hasebe; Yousuke Kouno; Shigeaki Kaga; Shoji Suzuki; Kanji Sugita
Journal:  Heart Vessels       Date:  2016-04-27       Impact factor: 2.037

10.  Immunoadsorption therapy for patients with dilated cardiomyopathy and heart failure.

Authors:  Uichi Ikeda; Hiroki Kasai; Atsushi Izawa; Jun Koyama; Yoshikazu Yazaki; Masafumi Takahashi; Makoto Higuchi; Chang-Sung Koh; Keiji Yamamoto
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.